For the second quarter of 2026, analysts expect Opus Genetics to report a consensus loss of $0.15 per share on revenue of $2.63 million, with the stock currently trading near $3.54 against an average analyst price target of $10.56. Investors are primarily focused on the company's clinical pipeline milestones, specifically the anticipated 3-month topline data from the OPGx-BEST1 Phase 1/2 trial expected in September 2026.
The firm, which recently merged with Ocuphire Pharma, has pivoted toward a pure-play gene therapy portfolio targeting inherited retinal diseases. Management has highlighted a robust cash runway extending into 2029, which is expected to support the advancement of multiple programs including the registrational Phase 3 dosing for its lead candidate, OPGx-LCA5.